SMT D002

Drug Profile

SMT D002

Alternative Names: DL 06003; SMT-D002

Latest Information Update: 14 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Summit plc
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Seborrhoeic dermatitis

Most Recent Events

  • 14 Mar 2013 No development reported - Phase-I for Seborrhoeic dermatitis in USA (PO)
  • 15 Apr 2008 Final efficacy data from a second phase I trial in Seborrhoea released by Summit
  • 23 Oct 2007 Summit plc has completed enrolment and initiated dosing in a second phase I trial for seborrhoea in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top